Ezose Sciences will explore glycans as a possible Parkinson's biomarker

The Michael J. Fox Foundation for Parkinson's Research is giving money to Ezose Sciences in New Jersey to look at the role that glycans play in Parkinson's disease. Neither party is discussing details of the grant, but Ezose will be using its GlycanMap technology to pursue the research. Glycans attach to proteins in the body and affect how they function biochemically, and the idea is that they might be connected to altered protein function as Parkinson's disease and other neurological disorders advance in the body. The hope is that glycans could become a new kind of biomarker that helps, in part, to guide drug development for new drugs for neurological disorders, and also helps better show disease mechanisms. Initial work will focus on glycan profiles in brainstem tissue from rat models of Parkinson's disease and also control rats. Release

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.